ARGX vs MRNA: argenx NV ADR and Moderna compared
The short version
From the latest prices and each company's SEC filings. Who's ahead on each measure, not which to buy.
- Moderna is the larger company, worth $81.0B, about 1.6 times argenx NV ADR.
- argenx NV ADR grew revenue faster over the last year (+88.6% vs +2.1%).
- argenx NV ADR keeps more of each dollar of revenue as operating profit (24.8% vs -149.0%).
Side by side
The stronger figure is shaded where higher (or, for valuation multiples, lower) reads as better. How the implied growth works.
| Measure | ARGX | MRNA |
|---|---|---|
| Market cap | $50.6B | $81.0B |
| Share price | $825.03 | $225.00 |
| Revenue (last fiscal year) | $4.2B | $1.9B |
| Free cash flow (last fiscal year) | $574M | -$2.1B |
| Revenue growth, last year | +88.6% | +2.1% |
| Revenue growth per year, last 5 fiscal years | +71.0% | -43.0% |
| Operating margin | 24.8% | -149.0% |
| Net margin | 30.4% | -141.4% |
| Return on equity | 43.5% | -46.6% |
| P/E (trailing) | 42.2x | — |
| Price / free cash flow | 60.0x | — |
| EV / EBITDA | 29.6x | — |
| FCF growth the price implies | 24.7% | — |
| Dividend yield | — | — |
| Debt / equity | 0.09x | 0.62x |
| Fundamental grade | B | F |
| Superinvestors holding it | 3 | 2 |
| Insider purchases, last 12 months | 0 | 2 |
Results from SEC filings
Revenue and free cash flow by fiscal year, from each company's 10-K filings.
argenx NV ADR
| Year | Revenue | Free cash flow | Op. margin |
|---|---|---|---|
| 2021 | $497M | -$728M | -70.1% |
| 2022 | $10M | -$967M | -7184.7% |
| 2023 | $36M | -$464M | -1196.2% |
| 2024 | $2.3B | -$151M | -0.96% |
| 2025 | $4.2B | $574M | 24.8% |
Moderna
| Year | Revenue | Free cash flow | Op. margin |
|---|---|---|---|
| 2021 | $18.5B | $13.3B | 72.0% |
| 2022 | $19.3B | $4.6B | 48.9% |
| 2023 | $6.8B | -$3.8B | -61.9% |
| 2024 | $3.2B | -$4.1B | -121.9% |
| 2025 | $1.9B | -$2.1B | -158.1% |
Where the revenue comes from
argenx NV ADR · by regions, 2023
United States$30M84%
China$6M16%
Moderna · by products, 2025
Net product sales$1.8B94%
Other revenue$126M6%
Compare them in fullFifteen years of statements, quarterly results, DCF and IRR models, and any number of peers side by side.
Open ARGX in InvestinglyQuestions
Which is bigger, argenx NV ADR or Moderna?
Moderna (MRNA), at $81.0B against $50.6B.
Which grows faster, ARGX or MRNA?
argenx NV ADR: revenue grew +88.6% over the last year, against +2.1%.
Prices and ratios as of the last daily update; statements from SEC filings. Information only, not investment advice.